Abstract: A novel method of treating diseases characterized by high PAI-1 is presented. Administering a composition comprising a therapeutically effective amount of genistein was found to inhibit PAI-1 promotor activity and decrease PAI-1 levels to treat diseases such as asthma, which exhibit increased PAI-1 levels. Genotyping the patient can be performed prior to administration to detect a 4G/5G polymorphism as patients having a 4G genotype have better response to the genistein treatment. The composition may be comprised of a therapeutically effective amount of genistein derived naturally from soybeans or synthetically produced and optionally present in nanoparticle form.

Abstract: Materials and methods for enhancing the effectiveness of proton radiation therapy (e.g., high linear energy transfer (LET) proton radiation therapy) against tumor cells are provided herein.

Abstract: Methods and materials and methods for reducing organ and tissue damage associated with inflammatory and immunological disorders are provided herein. For example, this document provides methods and materials for using genistein to treat respiratory distress syndrome or acute lung injury (e.g., pneumonitis, pulmonary fibrosis, dyspnea, pneumonia, and/or pulmonary edema resulting from viral infection, allergic responses, chemical insults, radiation, tissue injury, persistent infections, or autoimmune reactions).

Abstract: Materials and methods for enhancing the effectiveness of proton radiation therapy (e.g., high linear energy transfer (LET) proton radiation therapy) against tumor cells are provided herein.

Abstract: Materials and methods for using genistein to treat respiratory distress syndrome or acute lung injury (e.g., pneumonitis, pulmonary fibrosis, dyspnea, pneumonia, and/or pulmonary edema resulting from viral infection, including SARS-CoV-2 infection) are provided herein.

Abstract: Materials and methods for reducing, preventing, or mitigating the effects of exposure to ionizing radiation are provided herein.

Abstract: The present invention is directed to solid dispersion formulations comprising genistein and one or more pharmaceutically acceptable excipients. In particular embodiments, the one or more pharmaceutically acceptable excipients include polyvinylpyrrolidone. Various techniques can be used to form the solid dispersions, including spray drying and extrusion techniques.

Abstract: Materials and methods for reducing, preventing, or mitigating the effects of exposure to ionizing radiation are provided herein. In general, the methods can include administering a nanoparticulate genistein composition to a subject identified as having been exposed or at risk of being exposed to ionizing radiation, such as proton radiation.

Abstract: Materials and methods for enhancing the effectiveness of proton radiation therapy (e.g., high linear energy transfer (LET) proton radiation therapy) against tumor cells are provided herein.

Abstract: Materials and methods for enhancing the effectiveness of proton radiation therapy (e.g., high linear energy transfer (LET) proton radiation therapy) against tumor cells are provided herein.

Abstract: Materials and methods for reducing, preventing, or mitigating the effects of exposure to ionizing radiation are provided herein.

Abstract: The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.

Abstract: Materials and methods for enhancing the effectiveness of proton radiation therapy (e.g., high linear energy transfer (LET) proton radiation therapy) against tumor cells are provided herein.

Abstract: Mitigation of long and short-term detrimental effects of exposure to low dose ionizing radiation by administration of genistein in the form of a nanosuspension to a mammal in an amount effective for achieving genistein serum levels of between 1-5 ?M in the mammal throughout a time period from exposure to the ionizing radiation to twelve hours after exposure to the ionizing radiation.

Abstract: The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.

Abstract: Mitigation of long and short-term detrimental effects of exposure to low dose ionizing radiation by administration of genistein in the form of a nanosuspension to a mammal in an amount effective for achieving genistein serum levels of between 1-5 ?M in the mammal throughout a time period from exposure to the ionizing radiation to twelve hours after exposure to the ionizing radiation.

Abstract: Mitigation of long term detrimental effects of exposure to medical imaging ionizing radiation by administration of an amount of genistein in the form of a nanosuspension to someone effective for achieving genistein serum levels of between 1-5 ?M in the mammal throughout a time period from exposure to medical imaging ionizing radiation to twelve hours after exposure to medical imaging ionizing radiation.

Abstract: The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.

Abstract: The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.

Abstract: The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.